Chengxue Dang

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Xiaotian Zhang, Liang Han, Ziyu Li et al. · The Lancet Oncology · 2021 · 414 citations

D2 Gastrectomy, Surgical Oncology, Esophageal Cancer +10

The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study

Xin Xie, Kaijie Ren, Zhangjian Zhou et al. · BMC Gastroenterology · 2022 · 212 citations · Full text

Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF-κB signalling pathways

Xiaobin Ma, Chengxue Dang, Huafeng Kang et al. · International Immunopharmacology · 2015 · 104 citations

Inflammation, Nf-κb Signalling Pathways, Redox Signaling +9

Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer

Chengxue Dang, Yong Zhang, Qingyong Ma et al. · Journal of Gastroenterology and Hepatology · 2006 · 100 citations

Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer

Peng Xia, Han‐Xiang An, Chengxue Dang et al. · BMC Cancer · 2009 · 96 citations · Full text